Merck Partners On Alzheimer’s Diagnostic With GE Healthcare

Merck will use GE Healthcare’s investigational positron emission tomography agent flutemetamol to select patients to enroll in clinical trials for its Alzheimer’s disease drug candidate.

Merck & Co. Inc.is studying GE Healthcare’s investigational positron emission tomography imaging agent flutemetamol as a potential companion diagnostic for its Alzheimer’s disease therapy, MK-8931, under a partnership announced Dec. 18.

The announcement comes on the heels of Merck’s Dec. 3 announcement that it started a phase II/III study of the...

More from Clinical Trials

More from R&D